Accolate and Hepatotoxicity aggravated - a phase IV clinical study of FDA data

Summary:

Hepatotoxicity aggravated is reported only by a few people who take Accolate.

The phase IV clinical study analyzes which people take Accolate and have Hepatotoxicity aggravated. It is created by eHealthMe based on reports of 4,078 people who have side effects while taking Accolate from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Feb, 07, 2023

4,078 people reported to have side effects when taking Accolate.
Among them, 4 people (0.1%) have Hepatotoxicity aggravated.

What is Accolate?

Accolate has active ingredients of zafirlukast. It is often used in asthma. eHealthMe is studying from 4,153 Accolate users for its effectiveness, alternative drugs and more.

What is Hepatotoxicity aggravated?

Hepatotoxicity aggravated (serious chemical-driven liver damage) is found to be associated with 930 drugs and 320 conditions by eHealthMe.

Number of Accolate and Hepatotoxicity aggravated reports submitted per year:

Could Accolate cause Hepatotoxicity aggravated?

Time on Accolate when people have Hepatotoxicity aggravated *:

Gender of people who have Hepatotoxicity aggravated when taking Accolate *:

female: 100 %
male: 0.0 %

Age of people who have Hepatotoxicity aggravated when taking Accolate *:

Common drugs people take besides Accolate *:

Common side effects people have besides Hepatotoxicity aggravated *:

Hepatic Failure (liver failure): 2 people, 50.00%
Fatigue (feeling of tiredness): 2 people, 50.00%
Vision Blurred: 1 person, 25.00%
Dizziness (Excl Vertigo): 1 person, 25.00%
Hypoaesthesia (reduced sense of touch or sensation): 1 person, 25.00%
Hepatomegaly (abnormal enlargement of the liver): 1 person, 25.00%
Hepatitis Acute: 1 person, 25.00%
Hepatic Necrosis (large portions of liver die off due to severe liver disease): 1 person, 25.00%
Hearing Loss: 1 person, 25.00%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 1 person, 25.00%

* Approximation only. Some reports may have incomplete information.

Do you take Accolate and have Hepatotoxicity aggravated?

Check whether Hepatotoxicity aggravated is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Hepatotoxicity aggravated and when was it recovered:

Hepatotoxicity aggravated in Accolate

Expand to all the drugs that have ingredients of zafirlukast:

Hepatotoxicity aggravated and drugs with ingredients of zafirlukast

Alternative drugs to, pros and cons of Accolate:

Accolate (4,153 reports)

Common Accolate side effects:

Breathing difficulty: 536 reports
Asthma: 498 reports
Chest pain: 305 reports
Fatigue (feeling of tiredness): 276 reports
Drug ineffective: 267 reports
Weakness: 225 reports

Browse all side effects of Accolate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Hepatotoxicity aggravated treatments and more:

Hepatotoxicity aggravated (47 reports)

COVID vaccines that are related to Hepatotoxicity aggravated:

Common drugs associated with Hepatotoxicity aggravated:

How the study uses the data?

The study uses data from the FDA. It is based on zafirlukast (the active ingredients of Accolate) and Accolate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.